Cargando…
Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas
SIMPLE SUMMARY: Systemic peripheral T cell lymphomas (PTCL) are a rare and clinically and biologically heterogeneous group of disorders with scarce and generally low-quality evidence guiding their management. In this manuscript, we tackle the current controversies in the front-line treatment of syst...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818471/ https://www.ncbi.nlm.nih.gov/pubmed/36612216 http://dx.doi.org/10.3390/cancers15010220 |
_version_ | 1784864994080325632 |
---|---|
author | Sorigue, Marc Kuittinen, Outi |
author_facet | Sorigue, Marc Kuittinen, Outi |
author_sort | Sorigue, Marc |
collection | PubMed |
description | SIMPLE SUMMARY: Systemic peripheral T cell lymphomas (PTCL) are a rare and clinically and biologically heterogeneous group of disorders with scarce and generally low-quality evidence guiding their management. In this manuscript, we tackle the current controversies in the front-line treatment of systemic PTCL and give our thoughts vis-a-vis potential developments to come in the next few years. ABSTRACT: Systemic peripheral T cell lymphomas (PTCL) are a rare and clinically and biologically heterogeneous group of disorders with scarce and generally low-quality evidence guiding their management. In this manuscript, we tackle the current controversies in the front-line treatment of systemic PTCL including (1) whether CNS prophylaxis should be administered; (2) whether CHOEP should be preferred over CHOP; (3) what role brentuximab vedotin should have; (4) whether stem cell transplant (SCT) consolidation should be used and whether autologous or allogeneic; (5) how should molecular subtypes (including DUSP22 or TP63-rearranged ALCL or GATA3 or TBX21 PTCL, NOS) impact therapeutic decisions; and (6) whether there is a role for targeted agents beyond brentuximab vedotin. |
format | Online Article Text |
id | pubmed-9818471 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98184712023-01-07 Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas Sorigue, Marc Kuittinen, Outi Cancers (Basel) Review SIMPLE SUMMARY: Systemic peripheral T cell lymphomas (PTCL) are a rare and clinically and biologically heterogeneous group of disorders with scarce and generally low-quality evidence guiding their management. In this manuscript, we tackle the current controversies in the front-line treatment of systemic PTCL and give our thoughts vis-a-vis potential developments to come in the next few years. ABSTRACT: Systemic peripheral T cell lymphomas (PTCL) are a rare and clinically and biologically heterogeneous group of disorders with scarce and generally low-quality evidence guiding their management. In this manuscript, we tackle the current controversies in the front-line treatment of systemic PTCL including (1) whether CNS prophylaxis should be administered; (2) whether CHOEP should be preferred over CHOP; (3) what role brentuximab vedotin should have; (4) whether stem cell transplant (SCT) consolidation should be used and whether autologous or allogeneic; (5) how should molecular subtypes (including DUSP22 or TP63-rearranged ALCL or GATA3 or TBX21 PTCL, NOS) impact therapeutic decisions; and (6) whether there is a role for targeted agents beyond brentuximab vedotin. MDPI 2022-12-30 /pmc/articles/PMC9818471/ /pubmed/36612216 http://dx.doi.org/10.3390/cancers15010220 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sorigue, Marc Kuittinen, Outi Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas |
title | Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas |
title_full | Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas |
title_fullStr | Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas |
title_full_unstemmed | Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas |
title_short | Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas |
title_sort | controversies in the front-line treatment of systemic peripheral t cell lymphomas |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818471/ https://www.ncbi.nlm.nih.gov/pubmed/36612216 http://dx.doi.org/10.3390/cancers15010220 |
work_keys_str_mv | AT soriguemarc controversiesinthefrontlinetreatmentofsystemicperipheraltcelllymphomas AT kuittinenouti controversiesinthefrontlinetreatmentofsystemicperipheraltcelllymphomas |